MARKET

BCLI

BCLI

Brainstorm Cell Therapeutics I
NASDAQ
0.5275
+0.0025
+0.48%
Opening 12:56 04/24 EDT
OPEN
0.5150
PREV CLOSE
0.5250
HIGH
0.5500
LOW
0.5150
VOLUME
95.87K
TURNOVER
0
52 WEEK HIGH
3.373
52 WEEK LOW
0.1340
MARKET CAP
36.05M
P/E (TTM)
-1.3217
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at BCLI last week (0415-0419)?
Weekly Report · 2d ago
Brainstorm Cell Therapeutics Executive Leadership Changes
TipRanks · 04/17 10:12
BrainStorm Cell Therapeutics promotes Bob Dagher to Chief Medical Officer
Seeking Alpha · 04/17 07:25
Reported Earlier, BrainStorm Cell Therapeutics Announces Management Changes As It Plans Registrational Phase 3b Trial Of NurOwn
Benzinga · 04/17 06:54
Brainstorm Cell Therapeutics (BCLI) Price Target Increased by 150.00% to 2.55
NASDAQ · 04/17 05:19
BrainStorm Cell Therapeutics Loses Co-CEO Lindborg, Names Dagher as New Medical Chief
BrainStorm Cell Therapeutics named a new medical chief ahead of a long-awaited clinical trial. Co-Chief Executive Stacy Lindborg will step down but remain on the company's board. The New York-based company is developing stem-cell therapeutics. BrainStorm also named Bob Dagher as chief medical officer. Dagher will oversee a clinical trial of its therapy to treat ALS.
Dow Jones · 04/16 22:51
*BrainStorm Cell Therapeutics: Bob Dagher, MD, Promoted to Chief Medical Officer >GHDN.BE
Dow Jones · 04/16 22:33
*BrainStorm Cell Therapeutics: Dr. Stacy Lindborg Stepping Down as Co-CEO and Transitioning to Board of Directors >GHDN.BE
Dow Jones · 04/16 22:32
More
About BCLI
BrainStorm Cell Therapeutics Inc. is a developer of autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The neurodegenerative diseases include Amyotrophic Lateral Sclerosis (ALS), Progressive Multiple Sclerosis (PMS), Alzheimer’s disease (AD), and others. The Company is engaged in the clinical development and commercialization of the NurOwn technology platform used to produce autologous mesenchymal stem cells- neurotrophic factors (MSC-NTF) cells. NurOwn leverages cell culture methods to induce autologous bone marrow derived MSCs to secrete high levels of NTFs, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. Autologous MSC-NTF cells is for the treatment of ALS. It has completed a phase III trial in ALS. Its wholly owned subsidiary, BrainStorm Cell Therapeutics Ltd., holds exclusive rights to commercialize NurOwn technology.

Webull offers Brainstorm Cell Therapeutics Inc stock information, including NASDAQ: BCLI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCLI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BCLI stock methods without spending real money on the virtual paper trading platform.